Purpose

Evaluate effectiveness and safety in BRIUMVI® (ublituximab-xiiy) treated patients in real-world clinical practice. Observe patient demographics, baseline disease activity, and rationale for selecting BRIUMVI® (ublituximab-xiiy). 

Category

IRB Number
STUDY00000612
NCT Number
-
Open to Enrollment
Yes
Sponsor
-



Study Contact

Local Recruitment Point of Contact
Luis Garcia
210-450-8451
garcial38@uthscsa.edu

Principal Investigator
Tania Reyna

Regulatory Point of Contact
Jannel Gamboa
gamboaj1@uthscsa.edu

Regulatory Point of Contact
Charlotte Rhodes
210-450-8454
rhodesc1@uthscsa.edu

Regulatory Point of Contact
Luis Garcia
210-450-8451
garcial38@uthscsa.edu



Eligibility

Eligible Ages
-
Eligible Genders
Accepts Healthy Volunteers
No

Inclusion Criteria

    • ≥18 yr old patients with relapsing forms of MS 
    • Confirmed MS diagnosis
    • Patients who have not recieved BRIUMVI® infusion prior to enrollment
    • Patients prescribed BRIUMVI®, but have not yet recieved their first infusion on Day 1 of 150mg.

Exclusion Criteria

    • patients who have recieved any live or live-attenuated vaccines (including varicella-zoster virus or measles) within 4 weeks prior to first BRIUMVI® administration
    • Any non-live vaccines within 2 weeks prior to first BRIUMVI® administration
    • Any active infection (e.g., Hepatitis B Virus [HBV]) 
    • Concurrent interventional MS trials or planned concurrent treatment with others MS DMT during study period.